Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,33€(−92,29%). Der Median liegt bei +1,33€(−92,29%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.» Mehr auf zacks.com
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum
Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments. R289's promising pipeline progress and TAVALISSE's patent extension to 2032 bolster Rigel's long-term outlook, despite reliance on key products and competitive markets.» Mehr auf seekingalpha.com
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Kalpit Patel - B.» Mehr auf seekingalpha.com

Im letzten Quartal hatte RIGEL PHARMACEUTICALS INC einen Umsatz von 55,35 Mio€ und ein Nettoeinkommen von 13,78 Mio€